Nina D Russell

Summary

Affiliation: Bill and Melinda Gates Foundation
Country: USA

Publications

  1. ncbi request reprint Statistical considerations for the design and analysis of the ELISpot assay in HIV-1 vaccine trials
    Michael G Hudgens
    Public Health Sciences Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, NW 500, PO Box 19024, Seattle 98109 1024, USA
    J Immunol Methods 288:19-34. 2004
  2. pmc Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial
    Nina D Russell
    Program in Infectious Diseases, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    J Acquir Immune Defic Syndr 44:203-12. 2007
  3. ncbi request reprint Statistical evaluation of HIV vaccines in early clinical trials
    Zoe Moodie
    Statistical Center for HIV Aids Research and Prevention, Fred Hutchinson Cancer Reasearch Center, 1100 Fairview Ave N, LE 400, PO Box 19024, Seattle, WA 98109 1024, USA
    Contemp Clin Trials 27:147-60. 2006
  4. ncbi request reprint Moving to human immunodeficiency virus type 1 vaccine efficacy trials: defining T cell responses as potential correlates of immunity
    Nina D Russell
    Program in Infectious Diseases, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    J Infect Dis 187:226-42. 2003
  5. doi request reprint Novel directions in HIV-1 vaccines revealed from clinical trials
    Jean Louis Excler
    U S Military HIV Research Program MHRP, Bethesda, Maryland 20817, USA
    Curr Opin HIV AIDS 8:421-31. 2013
  6. ncbi request reprint Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults
    Geoffrey J Gorse
    Department of Veterans Affairs Medical Center and Saint Louis University, St Louis, MO 63104, United States
    Vaccine 26:215-23. 2008

Detail Information

Publications6

  1. ncbi request reprint Statistical considerations for the design and analysis of the ELISpot assay in HIV-1 vaccine trials
    Michael G Hudgens
    Public Health Sciences Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, NW 500, PO Box 19024, Seattle 98109 1024, USA
    J Immunol Methods 288:19-34. 2004
    ..Moreover, the proposed methods have potential utility in related HIV immunopathogenesis studies and in non-HIV clinical vaccine trials...
  2. pmc Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial
    Nina D Russell
    Program in Infectious Diseases, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    J Acquir Immune Defic Syndr 44:203-12. 2007
    ..We conducted a phase 2 trial to determine if a canarypox vaccine candidate (vCP1452) administered with rgp120 subunit protein would "qualify" for a trial to define a correlate of efficacy...
  3. ncbi request reprint Statistical evaluation of HIV vaccines in early clinical trials
    Zoe Moodie
    Statistical Center for HIV Aids Research and Prevention, Fred Hutchinson Cancer Reasearch Center, 1100 Fairview Ave N, LE 400, PO Box 19024, Seattle, WA 98109 1024, USA
    Contemp Clin Trials 27:147-60. 2006
    ..The goal of these early trials is to narrow the number of candidate vaccines to the most promising candidates worthy of further study in efficacy trials...
  4. ncbi request reprint Moving to human immunodeficiency virus type 1 vaccine efficacy trials: defining T cell responses as potential correlates of immunity
    Nina D Russell
    Program in Infectious Diseases, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    J Infect Dis 187:226-42. 2003
    ..When responses in natural infection were compared with vaccine-induced responses, vaccine recipient responses were > or =1 log lower, which confirms the importance of using this sensitive assay as an initial screen in vaccine protocols...
  5. doi request reprint Novel directions in HIV-1 vaccines revealed from clinical trials
    Jean Louis Excler
    U S Military HIV Research Program MHRP, Bethesda, Maryland 20817, USA
    Curr Opin HIV AIDS 8:421-31. 2013
    ..Put into perspective, the results from efficacy trials and the identification of correlates of risk have opened large and unforeseen avenues for vaccine development...
  6. ncbi request reprint Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults
    Geoffrey J Gorse
    Department of Veterans Affairs Medical Center and Saint Louis University, St Louis, MO 63104, United States
    Vaccine 26:215-23. 2008
    ..Three vaccine recipients raised anti-HIV-1 CD8+ CTL measured by chromium-release assay. The vaccine was safe and well-tolerated, but only weakly immunogenic...